| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGHG4 |
| Uniprot No | P01861 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 99-326aa |
| 氨基酸序列 | ESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQ EGNVFSCSVMHEALHNHYTQKSLSLSLE |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IGHG4重组蛋白的3篇模拟参考文献(基于常见研究主题的概括，非真实文献)：
---
1. **文献名称**：*Structural and functional characterization of recombinant human IgG4 antibodies*
**作者**：Smith A, et al.
**摘要**：本研究通过重组表达技术制备了人源IgG4抗体，分析了其独特的铰链区柔性结构和单特异性结合能力，揭示了IgG4在免疫调节中低效激活补体的分子机制。
---
2. **文献名称**：*IgG4-related disease pathogenesis: Role of recombinant IgG4 in fibroblast activation*
**作者**：Tanaka Y, et al.
**摘要**：通过体外实验证明，重组IgG4蛋白可通过结合Fcγ受体促进成纤维细胞增殖及纤维化因子分泌，为IgG4相关疾病(如自身免疫性胰腺炎)的病理机制提供了新见解。
---
3. **文献名称**：*Engineering stable IgG4-based therapeutic antibodies with reduced effector functions*
**作者**：Zhang L, et al.
**摘要**：报道了一种通过重组技术改造IgG4 Fc区域的方法，成功降低了抗体依赖性细胞毒性(ADCC)，优化了IgG4抗体在肿瘤靶向治疗中的安全性。
---
(注：以上为模拟内容，实际文献需通过PubMed/Google Scholar等平台检索关键词如“recombinant IgG4”、“IgG4 antibody engineering”等获取。)
**Background of IHG4 Recombinant Protein**
Immunoglobulin G4 (IgG4) is one of four subclasses of IgG antibodies, distinguished by its unique structural and functional properties. The IGHG4 gene encodes the constant region of the IgG4 heavy chain, which contributes to its characteristic features, including weak effector functions (e.g., reduced complement activation and Fc receptor binding) and dynamic Fab-arm exchange, enabling the formation of bispecific antibodies. These traits make IgG4 antibodies less inflammatory compared to other IgG subclasses, playing roles in immune tolerance and chronic antigen exposure responses.
Recombinant IGHG4 proteins are engineered in vitro using genetic techniques, often expressed in mammalian systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications. They are pivotal in biomedical research and therapeutic development. For instance, IgG4-based monoclonal antibodies (e.g., pembrolizumab, nivolumab) are widely used in cancer immunotherapy due to their prolonged half-life and minimized immune activation. Additionally, recombinant IgG4 proteins serve as tools to study immune dysregulation in IgG4-related diseases (IgG4-RD), a fibroinflammatory condition characterized by elevated IgG4 levels and tissue infiltration.
However, IgG4's functional duality presents challenges. While its anti-inflammatory profile is advantageous in therapies, its tendency to form immune complexes or undergo Fab-arm exchange may contribute to pathological mechanisms. Researchers utilize recombinant IGHG4 proteins to dissect these processes, optimize therapeutic designs, and develop diagnostic assays.
In summary, IGHG4 recombinant proteins bridge fundamental immunology and clinical applications, offering insights into immune modulation while driving innovations in treating cancers, autoimmune disorders, and IgG4-RD. Their study remains critical for balancing therapeutic efficacy with safety in antibody engineering.
×
